

## Contact Us

GenScript is dedicated to serving pharmaceutical and biotech companies in the areas of drug discovery and development. With a global presence and local access, GenScript provides high-quality biology CRO services and around-the-clock account support to our customers all over the world. Contact us any time.

### Contact:

#### All Correspondence

GenScript USA Inc.  
860 Centennial Ave.  
Piscataway, NJ 08854  
U.S.A.

Email: [info@genscript.com](mailto:info@genscript.com)

Tel: 1-877-436-7274 (Toll-Free)

Tel: 1-732-885-9188, 1-732-885-9688

Fax: 1-732-210-0262, 1-732-885-5878

#### Business Development:

Email: [bd@genscript.com](mailto:bd@genscript.com)

Tel: 1-732-317-5088

#### Regional Numbers:

Australia: 1-800-172-605 (Toll-Free)

Belgium: 32-27-470-921

Denmark: 8088-7617 (Toll-Free)

France: 08-05-10-22-28 (Toll-Free)

Finland: 0800-913-020 (Toll-Free)

Germany: 0-800-0006-320 (Toll-Free)

Hong Kong: 800-964-684 (Toll-Free)

Ireland: 1800-932-547 (Toll-Free)

Israel: 1-809-216-068 (Toll-Free)

Japan: 81-3-6206-8985

Netherlands: 31-20-890-5456

Norway: 800-19-172 (Toll-Free)

Portugal: 800-815-627 (Toll-Free)

Singapore: 800-120-4549 (Toll-Free)

Spain: 800-098-920 (Toll-Free)

Sweden: 0200-884-573 (Toll-Free)

Switzerland: 0800-369-254 (Toll-Free)

United Kingdom: 08082-380203 (Toll-Free)

#### Global Services




**CALL NOW FOR MORE INFORMATION**

**1-732-885-9188**

GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA

Fax: 1-732-210-0262 Web: [www.genscript.com](http://www.genscript.com) Email: [info@genscript.com](mailto:info@genscript.com)

# GenScript



## The Biology CRO

**Bio-Reagent Center**

**Bio-Assay Center**

**Lead Optimization Center**

**Antibody Drug Development Center**



## Your Innovation Partner in Drug Discovery

The pharmaceutical industry is facing unprecedented competitions and challenges. Introduction of new medicines of safety and efficacy to the market is crucial to the growth and success of the business, but the pharmaceutical R&D output has declined in an alarming rate. Imperative challenges consist of shortening target identification and validation process, developing quality assay and screening, improving compound profiling and optimization, increasing success rate while containing cost, and bringing new therapy to market continuously, thus remaining productive and competitive.

GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on our assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations. Headquartered in New Jersey, USA and with a major subsidiary in China, GenScript has over 800 employees, many of them are seasoned R&D scientists from leading Western pharmaceutical and biotech companies with extensive experience in advancing drug discovery and development programs. We strive with competence and confidence to meet your demand for developing pre-clinical drug candidates time-efficiently and cost-effectively. With proven track record, GenScript is your ideal and reliable innovation partner in drug discovery.

## GenScript at a Glance

- Founded in 2002, we now employ over 800
- Seasoned science and management teams
- Global presence with local access
- 24-hour customer support
- Major operations in China
- ISO 9001:2008-certified
- Animal facility with AAALAC accreditation
- Full client IP protection

## Key Facts about GenScript

- We are the largest biology CRO in China.
- We are a leading gene synthesis provider in the world.
- We offer the best antibody service guarantees in the industry.
- We provide one-stop biology contract research services for early drug discovery in both small and large molecules.
- We offer advanced bioinformatics tools and IT infrastructure for value-added services, maximizing the client's convenience and satisfaction.
- Our customers include top pharmaceutical companies, major biotech firms, and research institutions in over 70 countries.



## GenScript CRO Service Modules

**Bio-Reagent Center**

- Molecular Biology Services
- Custom Protein Services
- Custom Peptide Services
- Custom Antibody Services
- Custom Cell Line Development

**Bio-Assay Center**

- Assay Development
- HTS Assay Conversion
- Specificity Assay
- Secondary Assay
- Compound Screening

**Lead Optimization Center**

- Hit-to-Lead
- Lead Optimization

**Antibody Drug Development Center**

- Antibody Humanization
- Affinity Maturation
- Bioprocess and Antibody Production


## The Value GenScript Adds to Your Business

Our well-integrated services and unique operation model add following values allowing you to:

- Tap into large talent pool with expertise in multiple functional areas.
- Access to special technology, additional capacity, extra headcount, and flexible scheduling.
- Receive seamless communication, around-the-clock support, standard documentation, and timely delivery.
- Accelerate drug discovery and development program with increased efficacy and reduced cost.
- Secure full IP protection with complete confidentiality and multiple layers of security measures.
- Foster a long-term strategic partnership with a reliable and proven CRO such as GenScript that offers a comprehensive portfolio of drug discovery services.

## Our Customers

Our track record speaks for itself. GenScript has served clients from top pharmaceutical companies, biotech firms, and major research institutions in 70 countries worldwide.



## Customer Testimonials

"I think GenScript provides absolutely excellent products in a timely fashion. I have primarily used GenScript to order codon optimized artificial genes. Ordering artificial genes on their website or via Email makes this especially facile because I can simply inquire about a gene, get a quote and then get a quote. The whole process is fast and the turnaround time for obtaining the finished product is usually less than a month. I also think their technical support are wonderful people, they have been most helpful in facilitating the process. I am so impressed with them that I have recommended them to several of my colleagues."

— Dr. Maria Schumacher, The M.D. Anderson Cancer Center, University of Texas

"GenScript is the company that I have entrusted my project with. The delivery of your gene synthesis is on time and the OptimumGene™ technology on your Gene-on-Demand® gene synthesis platform has increased my gene expression dramatically. I am very happy with my results and GenScript is always my first choice for gene services."

— Bin He, Bristol-Myers Squibb, USA

"I ordered from GenScript 3 different polyclonal antibodies directed to the peptide sequences I have selected as unique ones from the proteins we have been working on. In all cases this was a full service from peptide synthesis, KLH coupling, immunization and affinity purification. All three antibodies worked very nicely in Western, immunoprecipitation and immunocytochemistry."


— Prof. Katarzyna Nalecz, Nencki Institute of Experimental Biology, Poland

"GenScript Western kits have saved me weeks or months of research time! I absolutely love them! And the customer service is excellent, friendly and efficient."

— Dr. Sarah Yohannan, Yale University School of Medicine

## We Grow Toward Our Mission

We strive to accelerate the discovery and development of medicines and therapies, and ultimately to save lives and improve the welfare of human beings.



## Selected Publications

A total of 585 research articles have been published between 2004-2009, citing GenScript's services and products.

### Gene

- Sean Chapman, Christine Faulkner, Eirini Kaiserli, Carlos Garcia-Mata, Eugene I. Savenkov, Alison G. Roberts, Karl J. Oparka, and John M. Christie. The photoreversible fluorescent protein iLOV outperforms GFP as a reporter of plant virus infection. *PNAS*. Dec 2008; 105(50): 20038 - 20043
- Mridula Rewal, Rachel Jurd, T. Michael Gill, Dao-Yao He, Dorit Ron, and Patricia H. Janak.  $\alpha$ 4-Containing GABAA Receptors in the Nucleus Accumbens Mediate Moderate Intake of Alcohol. *J. Neurosci.* Jan 2009; 29(2): 543 - 549

### Protein

- Cheng Du, Meena Jaggi, Chuanyou Zhang, and K.C. Balaji. Protein Kinase D1-Mediated Phosphorylation and Subcellular Localization of  $\beta$ -Catenin. *Cancer Res.* Feb 2009; 69(3): 1117 - 1124
- Mala M. Shah, Michele Migliore, Ignacio Valencia, Edward C. Cooper, and David A. Brown. Functional significance of axonal Kv7 channels in hippocampal pyramidal neurons. *PNAS*. Jun 2008; 105(22): 7869 - 7874

### Peptide

- Dazhi Lai, Mimi Wan, Jie Wu, Paula Preston-Hurlburt, Ritu Kushwah, Thomas Grundström, Anthony N. Imbalzano, and Tian Chi. Induction of TLR4-target genes entails calcium/calmodulin-dependent regulation of chromatin remodeling. *PNAS*. Jan 2009; 106(4): 1169 - 1174
- Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, Ten Cate H, Spek CA. Protease-activated receptor-4 inhibition protects from multi-organ failure in a murine model of systemic inflammation. *Blood*. Nov 2007; 110(9): 3176 - 3182

### Antibody

- Wang Y, Tandan S, Cheng J, Yang C, Nguyen L, Sugianto J, Johnstone JL, Sun Y, and Hill JA. CaMKII-dependent remodeling of Ca<sup>2+</sup> current in pressure-overload heart failure. *J. Biol. Chem.* Sep 2008; 283(37): 25524 - 25532
- Pablo A. González, Carolina E. Prado, Eduardo D. Leiva, Leandro J. Carreño, Susan M. Bueno, Claudia A. Riedel, and Alexis M. Kalergis. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. *PNAS*. Sep 2008; 105(39): 14999 - 15004

## Bio-Reagent Service Center

We at GenScript have developed advanced genomic, transcriptomic, and proteomic technologies designed to accelerate our clients' drug discovery programs. GenScript's Bio-Reagent Center boasts world-class talent and state-of-the-art equipment, providing superior services and products in the most time-efficient and cost-effective manner.

With a scientific team sporting a total of over 1,000 years of industrial experience in bio-reagent services, and a track record of delivering over 90% of all orders on time, GenScript offers clients and strategic partners guaranteed satisfaction and the benefits of our economy-of-scale and broadness-of-scope bio-reagent services in molecular biology, custom peptides, custom proteins, custom antibody production, and custom cell line development.



### Molecular Biology Services

—Largest Gene Synthesis Supplier in the U. S.

GenScript provides a comprehensive repertoire of molecular biology services, ranging from gene cloning and characterization to advanced genetic engineering and gene libraries. We have delivered over 100,000 synthetic genes and constructs with the most complex and difficult traits through our Gene-on-Demand<sup>®</sup> *de novo* synthesis platform. Our proprietary CloneEZ<sup>®</sup> technology is capable of placing any gene in any vector independent of restriction and ligation, seamlessly. Our CloneArch<sup>™</sup> System provides our customers with worry-free clone storage and a portal to all molecular biology, simply one-click away.

- Gene synthesis
- PCR cloning and subcloning
- Mutagenesis
- Mutant libraries
- Plasmid preparation
- siRNA and miRNA
- KI/KO vector construction
- Expression vector construction
- Large-scale DNA sequencing
- CloneArch<sup>™</sup> clone storage and management



### Custom Peptide Services

—FlexPeptide<sup>™</sup> Ensures Delivery and Quality

GenScript's proprietary FlexPeptide<sup>™</sup> platform provides custom peptides of up to 200 residues in length and a capacity of 6,000 peptides per month. With a scale ranging from milligrams to kilograms, comprehensive labeling and modification options, and rapid high-throughput peptide library synthesis, this platform is ideal choice for peptide synthesis, peptide library services and click peptide service. GenScript also offers large-scale cGMP-grade peptide and cosmetic peptide production service.

- Peptide synthesis
- Extensive chemical modifications
- Custom peptide library services
- Cosmetic peptide synthesis
- Recombinant peptides
- cGMP peptide synthesis
- Click peptide service

### Custom Protein Services

—Your Reliable Source for Functional Proteins

GenScript's protein team has extensive experience in codon optimization, protein refolding, solubility enhancement, and activity preservation in multiple expression systems. We have delivered over 3,000 batches of soluble and active proteins for assay development, compound screening, antigen generation, structural analysis, and many other drug discovery applications. Some of these orders are at scale of gram quantities or greater.

- Bacterial expression system
- Yeast expression system
- Baculovirus/insect cell expression system
- Mammalian cell expression system
- Soluble expression or refolding
- Fermentation up to 1,000 L
- Affinity and conventional purification
- Functional protein production



### Custom Antibody Services

#### —Best Guarantees in the Industry

GenScript provides one-stop solution to all of your antibody needs. For custom polyclonal antibodies, we guarantee an ELISA titer of 1:32,000 or better. For monoclonal antibodies, we guarantee two positive clones and positive Western results for qualified antigen. All this is made possible by our proprietary OptimumAntigen™ design tool, T-Max™ adjuvant, and cutting-edge nanotechnology. Our animal facility is AAALAC International accredited.

- Custom polyclonal antibody services
- Custom monoclonal antibody services
- Express antibody services
- Western-GUARANTEED antibody services
- Immunoassay development services
- Antibody purification and characterization
- Large-scale antibody production up to grams




### Custom Cell Line Services

#### —Custom Solutions for Stable Expression

With state-of-the-art facilities and seasoned industry experience, GenScript offers quality services for generating and evaluating primary clones for productivity and adaptability in serum-free suspension culture, identifying cell lines for stable, long-term production and scalability, and for developing large-scale purification and analytical processes. We also provide assay-ready frozen cells, preserving your time for high-value projects.

- Stable cell line services for protein and monoclonal antibody production
- Custom stable cell line services for assay development
- Transient gene expression service
- Process development and transfer
- Ready-to-Use™ frozen cells
- Cell membrane preparation



### Bio-Assay Center

With state-of-the-art facility and instruments and experienced scientist team, GenScript offers flexible solutions for screening against pharmaceutical targets of your interest which may include GPCRs, ion channels, kinases, proteases, and miscellaneous enzymes. Build on a solid foundation of reagent preparation capability, GenScript's competence in protein expression, cell and membrane preparation further validate our assay services and ensure a smooth work flow. With a track record of having developed two hundred of catalog assays for your immediate screening/profiling, we are committed to streamline your intended screening project and help you speed up the drug discovery process.

#### State-of-the-Art Instruments:

- FLIPR™<sup>Tetra</sup> Fluorometric Imaging Plate Reader
- FlexStation™ 3 Microplate Reader
- PHERAstar Plus
- QPatch-16 Screening Station
- TopCount™ Microplate Scintillation and Luminescence Counter
- Odyssey™ Infrared Imaging System
- Biomek™ NX Laboratory Automation Workstation

#### Catalog Assay Services:

- 100+ GPCRs: FLIPR calcium assays, reporter gene assays, and radioligand binding assays
- 50+ kinases: HTRF™ Transcreener™ ADP assays
- 30+ proteases and miscellaneous enzymes: Various well-validated assay methods
- hERG patch clamping assays
- CYP-mediated drug-drug interaction assays

## Lead Optimization Center

Our flagship bio-reagent and comprehensive bio-assay services, and the partnership with an established discovery chemistry company allow us to provide both exploratory and full medicinal chemistry services as well as discovery biology services for assessing quantitative structure-activity relationships (QSAR) of clients' lead compounds. We offer custom organic synthesis, custom peptide synthesis, intermediate and active drug substance production under GMP requirements, high-value focused library design and synthesis, primary and secondary assays for advancing compounds from hit to lead, and lead optimization.

### ▪ Hit-to-Lead:

- Profile customer's hit compounds
- Design and synthesize focused libraries around the hits
- Develop and set up biology assay and test the library compounds
- Analyze screening results and generate QSAR
- Report project status in standard or client-specified format

### ▪ Lead Optimization:

- Analyze current QSAR and propose plans for further optimization
- Use molecular modeling and QSAR for data analysis and drug design
- Perform multiparameter optimization: Biochemical potency, efficacy and toxicity, selectivity, PK, and PD
- Synthesize high-value library compounds for screening against targets
- Provide traditional medicinal chemistry effort



## Antibody Drug Development Center

With competency in recombinant engineering, transient expression, stable cell line development, and bioprocess development, GenScript provides custom solutions to the screening, optimization, and large-scale production of monoclonal antibodies for clinical development and therapeutic applications. We pay close attention to every single detail in upstream and downstream.

### Antibody Engineering

- mAb sequencing
- Chimeric antibody generation
- Epitope mapping
- Hybridoma stabilization
- Antibody humanization
- Antibody affinity maturation

### Bioprocess Development and Antibody Production

- Antibody production through transient and stable expression on flexible scales
- Stable cell line development for preclinical studies and clinical development
- Expertise in several types of cell lines including hybridoma, CHO, BHK, NS0, and 293 cells
- Serum-free or ADC-free medium development and optimization
- Upstream and downstream platform process development
- Production capacity ranging from milligrams to 100+ grams
- Single-use or disposable systems
- Quality assurance and fast turnaround time in process development and production, minimizing regulatory challenges

## Our Management Team

### **Frank Zhang, PhD, CEO**

Duke University, PhD, 1995; Schering-Plough, 1995-2002

Prior to co-founding GenScript, Dr. Zhang was an Associate Principal Scientist at Schering-Plough, where he led projects in human genome research, target identification, and anticancer drug discovery. In 2001, he received a Presidential Award for his achievements. He is the author of numerous scientific publications and is named as an inventor on four patent applications.

### **Larry Wang, PhD, President**

Rutgers University, PhD, 1996; Schering-Plough, 1996-2002

Prior to co-founding GenScript, Dr. Wang was a Senior Principal Scientist at Schering-Plough. As one of the key inventors on Zetia target discovery, his work advanced the understanding of intestinal cholesterol pathways. He received a Schering-Plough Presidential Award for his work on GPCR target discovery and a Gallo Award from the Cancer Research Institute of New Jersey. He has authored over 20 scientific publications.

### **Sally Wang, Executive Vice President**

Wuhan University, MS, 1990; Shenzhen Environmental Protection Bureau, Engineer, 1993-2000

As one of GenScript's co-founders, Ms. Wang developed strategic marketing and sales operations for the company. She has been providing leadership in day-to-day sales operations, custom service, and technical support since the company's inception. Prior to GenScript, she was an engineer and project leader at Shenzhen Environmental Protection Bureau in China.

### **James Xiao, PhD, Executive Vice President**

Hunan University, PhD, 1990; Faculty of Pharmacy of Porto University, 1991-1999; Hovione PharmaScience, 1999-2005; Shanghai Wuxi PharmaTech, 2005-2006; Hailing Chemipharma, 2006-2008

Formerly the vice general manager at Hailing Chemipharma; the Senior Director of Quality Control (QC) at Shanghai Wuxi PharmaTech and Head of QC and quality manager at Hovione PharmaScience, Dr. Xiao has ten years of management experience both in API and finished products. His achievements include managing first-class QC operations and establishing cGMP systems.

### **Nick Yan, PhD, MBA, Vice President, Marketing**

Cornell University, PhD, 1990; Fairleigh Dickinson University, MBA, 2000; BMS, 1993-2002; Wyeth Pharmaceuticals, 2006-2008

Dr. Yan was a Scientific Director at Wyeth, Medical Director at Pinnacle Communications Groups, Associate Director at Helix Medical Communication, Senior Analyst at Acumen Sciences, and Senior Research Investigator at Bristol-Myers Squibb. With a total of 20 years of industry experience, Dr. Yan is an accomplished professional in drug discovery, medical marketing, healthcare communication, continuing education, and publication strategies. He is six-term Executive Council Member of Sino-American Pharmaceutical Professionals Association (SAPA).

### **John Wang, PhD, Vice President, Bio-Reagent Division**

Rutgers University, PhD, 1998; Columbia University, 1998-1999; PharmaSeq, 1999-2003

Formerly a Senior Scientist at PharmaSeq, Dr. Wang holds many patents. At GenScript, he has contributed to the development of our innovative ONE-HOUR Western™ Kits and many other products, such as siRNA expression vectors for target gene silencing. Dr. Wang has established the platform that GenScript uses to develop new technologies.

### **Timothy Xia, PhD, Vice President, Protein Science & Assay Development Division**

Chinese Academy of Sciences, PhD, 1988; Guthrie Research Institute, 1993-1994; Viral Therapeutics, Inc. 1994-1998; Sanofi-Aventis, 1998-2008

Dr. Xia has over 25 years of experiences in protein production and lead identification for the development of therapeutic proteins for animal test and preclinical trial. He was Principle Investigator at Sanofi-Aventis in the field of protein production and engineering, R&D scientist at Viral Therapeutics, Inc. and Research Scientist at Guthrie Research Institute.

### **Louis Liu, MD, Vice President, Antibody Drug Discovery Division**

Norman Bethune University, MD, 1985; H.T. I. Bio-Products, 1997-1999; Strategic BioSolutions, 1999-2000; Rockland Immunochemicals, 2000-2006

Dr. Liu has more than 20 years of experience in immunoassay development, cell fusion, and hybridoma cell line development, and monoclonal and polyclonal antibody preparation. He has led the development of more than 1,000 hybridoma cell lines. In addition, he has successfully developed a number of immunoassays for compound detection in preclinical studies, clinical trials, and immunogenicity evaluation.

### **Jibin Yu, MS, Vice President, Biology Discovery**

Suzhou University, MS, 2002; Invitrogen, 2002-2004

Prior to GenScript, he worked in Invitrogen as the Director of the production department from 2002 to 2004. With an extensive experienced in gene engineering, Mr. Yu joined GenScript in 2004. As one of the local core management team member, Mr. Yu has assisted the headquarter to establish the production platforms and research centre at local site. He also collaborated to build up a powerful scientific team and setup the business operation process.

### **Ethan Yu, MD, PhD, Director, Sales Department**

Norman Bethun University, MD, 1987; Kyushu University, PhD, 1994; Eli Lilly & company, Cubist Pharmaceuticals, and SelectX Pharmaceuticals, 1999-2009

Dr. Yu has more than 10 years of industry experience in anti-infective, anti-viral and Type II diabetes drug discovery. He has gained extensive scientific experience in protein biochemistry, enzyme kinetics, assay development & HTS, lead characterization and optimization. Prior to GenScript, he was a Scientific Advisor for Linden Biosciences, Inc. and CEO of Walterson Biotechnology overseeing both marketing and sales.

### **Brian Manning, PhD, MBA, Director, Business Development**

U.C.D. National University of Ireland, PhD, 1992; Rensselaer Polytechnic Institute, MBA, 2005; Pfizer, 1999-2009

Dr. Manning was a Senior Principal Scientist at Pfizer Global R&D where he gained extensive experience in all aspects of plate-based pharmacology and screening technologies. He also acted as business liaison for multiple outsourced Cardiovascular and Metabolic Disease drug discovery programs with Asian CROs. In 2003, he received the Pfizer Global R&D Achievement Award for his work on standardization of global screening technologies and procedures. Dr. Manning has published more than 12 scientific publications and has been invited to speak at numerous international conferences.

### **John Shen, MD, PhD, MBA, Director, Business Development**

Ohio State University of Toledo, PhD, 1998; University of Michigan, MBA, 2008; Pfizer, 1998-2009

Dr. Shen was a Lab Manager at Pfizer Global R&D responsible for assay development and ultra high throughput screening (uHTS) supporting various Therapeutic Areas, and then Associate Director and Strategic Project Lead in Development Operations. John and his team promoted cutting edge nano technology for assay miniaturization, and supported the Ann Arbor discovery by improving productivity and data quality.

**Paul G.J. van Stralen, PhD, Director, Business Development Europe**

Erasmus University Medical School (NL), PhD, 1995; Promega, 2003-2009

Dr. van Stralen received his PhD degree in expression cloning strategies for target discovery of thyroid hormone transport from the department of Internal Medicine of the Erasmus University in Rotterdam. In 1995, he started pursuing a career in industrial sales and marketing. Since then, he worked for an international distributor company selling products for New England Biolabs and several other life science suppliers. He has helped setup the Molecular Diagnostics business of these suppliers in the Netherlands, Belgium, and Luxemburg. Before joining GenScript, he worked for Promega as part of the European Sales Managers team and the global CRM development team.

**Hideki Yakushiji, MS, Director, Business Development**

Graduate School of Science, Hokkaido University, MS, 1999; Sigma Aldrich and Genosys, 2002-2008,

Mr. Yakushiji has over 10 years of experience in science related marketing, including analytical instruments as well as bio and chemical reagents. He worked in Business Development dept. of Sigma Aldrich Japan, where he was in charge of Custom Business, marketing of Bio-Reagent and Hi-Tech materials. He also actively maintained in- and out-licensing and collaborations with 3<sup>rd</sup> party commercial and academic institutes. Mr. Yakushiji's extensive experience in areas of instrumentation, analytical chemistry and biology give him an edge in satisfying customers' demand to the maximum.

**Sean Li, PhD, Director, Peptide Department**

Beijing University, PhD, 1996; Osaka National Research Institute, 1999-2001; Purdue University, 2001-2004; University of Maryland Biotechnology Institute, 2005-2007

With more than 10 years of experience in protein and peptide design, synthesis, purification, and characterization, Dr. Li has played a key role in establishing GenScript's technology platforms for custom peptide synthesis. He is the author of numerous scientific publications.

**Oliver Zhang, PhD, Director, Antibody Drug Development**

Institute of Microbiology, CAS, MS, 1988; University of Heidelberg, PhD, 1998. Research Officer, Institute for Biological Sciences, CNRC, 2000-2009.

Dr. Zhang has more than 10 years of experience in process design for antibody engineering; antibody library design and construction and antibody isolation through phage display and further affinity maturation. He has authored dozens of research articles in premier scientific journals and received seven patents. Prior to GenScript, he was a research officer of Institute for Biological Sciences, National Research Council, Ottawa, Canada.

**Stanley Wang, PhD, Director, Discovery Biology/Assay Development**

University of Illinois at Urbana-Champaign, PhD in Biochemistry, 1989; Schering-Plough, 1992-2008

As a senior veteran from the pharmaceutical industry, Dr. Wang is experienced in discovery biology, assay development and discovery technologies. He has authored dozens of research articles in premier scientific journals and received several patents.


**Wen-Che Suen, PhD, Director, BioProcess Department**

University of Iowa, 1991; Schering-Plough, 1997-2008; Laureate Pharma, 2008-2009


Dr. Suen has more than 15 years of extensive experience in pharmaceuticals/biotechnology industry. He involved in the development and production of small molecule and biological drugs from lab to pilot plant scale. He specializes in protein expression, engineering, and purification as well as cell line and bioreactor process development using mammalian, insect, and microbial cultures. Dr. Suen has a total of 26 publications/presentations in peer-review journals and international conferences.

Your Reliable Partner

We Offer Integrated Services to Match Your Drug Discovery Process



Our Business Model



Our IP Protection

IP protection is a crucial part of the partnerships that we form with pharmaceutical clients. We provide full client IP protection through multiple layers of security measurement.



- Non-use, non-disclosure, and confidentiality agreements for every contract research project
- Secure online information transfer
- Account-specific document management
- Strict access control for dedicated research areas
- Confidentiality agreements are signed by all employees, who undergo regular IP awareness training
- Strict day-to-day SOP execution and information compartmentalization